Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mapracorat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 20/20 | 0.70 |
| ▸ | PGR | P06401 | 12/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 12/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mapracorat SCHEMBL31390417 | 1.00 | NR3C1 (0.70) | NR3C1PGRNR3C2AR | |
| Mapracorat SCHEMBL31390395 | 1.00 | NR3C1 (0.70) | NR3C1PGRNR3C2AR | |
| Mapracorat SCHEMBL29367060 | 1.00 | NR3C1 (0.70) | NR3C1PGRNR3C2AR | |
| Mapracorat SCHEMBL4531322 | 1.00 | NR3C1 (0.70) | NR3C1PGRNR3C2AR | |
| Mapracorat SCHEMBL31390404 | 1.00 | NR3C1 (0.70) | NR3C1PGRNR3C2AR | |
| Mapracorat SCHEMBL1877067 | 1.00 | NR3C1 (0.70) | NR3C1PGRNR3C2AR | |
| SCHEMBL15096316 | 0.91 | NR3C1 (0.57) | NR3C1PGRNR3C2AR | |
| SCHEMBL14147024 | 0.91 | NR3C1 (0.57) | NR3C1PGRNR3C2AR | |
| SCHEMBL14294790 | 0.89 | NR3C1 (0.55) | NR3C1PGRNR3C2AR | |
| SCHEMBL31390410 | 0.88 | NR3C1 (0.70) | NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126997-B1 | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma | NORTHWESTERN UNIVERSITY (US) | 2015-09-08 | — | — | US | claimed |
| US-8282909-B2 | Pharmaceutical composition for topical application of poorly soluble compounds | INTENDIS GMBH (DE) | 2012-10-09 | — | — | US | claimed |
| EP-2182918-A2 | PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION OF POORLY SOLUBLE COMPOUNDS | Intendis GmbH (DE) | 2010-05-12 | — | — | EP | claimed |
| EP-1844039-B1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AG (DE) | 2009-07-15 | — | — | EP | claimed |
| EP-2016935-A1 | Pharmaceutical composition for topical application of poorly soluble compounds | Intendis GmbH (DE) | 2009-01-21 | — | — | EP | claimed |
| US-20090016969-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION OF POORLY SOLUBLE COMPOUNDS | INTENDIS GMBH (DE) | 2009-01-15 | — | — | US | claimed |
| WO-2009007137-A2 | PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION OF POORLY SOLUBLE COMPOUNDS | INTENDIS GMBH (DE) | 2009-01-15 | — | — | WO | claimed |
| US-7417056-B2 | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2008-08-26 | — | — | US | claimed |
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | US | claimed |
| US-12496304-B2 | Selective glucocorticoid receptor modifiers for treating impaired skin wound healing | AKRIBES BIOMEDICAL GMBH (AT) | 2025-12-16 | — | — | US | disclosed |
| EP-3768324-B1 | METHODS FOR MODULATING INNATE LYMPHOID CELL ACTIVITY, ANTIBODY DRUG CONJUGATES AND USES IN THERAPY | INST NAT SANTE RECH MED (FR) | 2025-11-26 | — | — | EP | disclosed |
| EP-3914249-B1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | AKRIBES BIOMEDICAL GMBH (AT) | 2024-05-01 | — | — | EP | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220047602-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | AKRIBES BIOMEDICAL GMBH (AT) | 2022-02-17 | — | — | US | disclosed |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | SALIX PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | SALIX PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | SALIX PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| EP-1844039-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-17 | — | — | EP | disclosed |
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006050998-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | NFKBIA, PTGS2, PTGES2 | NR3C1 2604/4885PGR 3086/4885NR3C2 1476/4885 |
| US-20220047602-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 82/4885NR3C2 2/4885 |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | NR3C1, GCGR, GPBAR1 | NR3C1 1/4885PGR 45/4885NR3C2 15/4885 |
| US-12496304-B2 | Selective glucocorticoid receptor modifiers for treating impaired skin wound healing | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 82/4885NR3C2 2/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | NR3C1 1628/4885PGR 3140/4885NR3C2 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.